Pharma & Healthcare
Solid Tumor Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 18, 24
- ID: 553781
- Pages: 114
- Figures: 179
- Views: 1
The global market for Solid Tumor Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Solid Tumor Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Solid Tumor Drug by region & country, by Type, and by Application.
The Solid Tumor Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumor Drug.
Market Segmentation
By Company
AstraZeneca
Biogen
Baxter
Celgene Corporation
Abbott Laboratories
Pfizer Inc
Amgen Limited & Amgen Ireland Limited
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Johnson & Johnson
Segment by Type:
Small Molecules
Biologics
Segment by Application
Oncology
Neurology
Radiology
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Solid Tumor Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Solid Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Solid Tumor Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Solid Tumor Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Solid Tumor Drug by region & country, by Type, and by Application.
The Solid Tumor Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumor Drug.
Market Segmentation
By Company
AstraZeneca
Biogen
Baxter
Celgene Corporation
Abbott Laboratories
Pfizer Inc
Amgen Limited & Amgen Ireland Limited
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Johnson & Johnson
Segment by Type:
Small Molecules
Biologics
Segment by Application
Oncology
Neurology
Radiology
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Solid Tumor Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Solid Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Solid Tumor Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Solid Tumor Drug Product Introduction
1.2 Global Solid Tumor Drug Market Size Forecast
1.3 Solid Tumor Drug Market Trends & Drivers
1.3.1 Solid Tumor Drug Industry Trends
1.3.2 Solid Tumor Drug Market Drivers & Opportunity
1.3.3 Solid Tumor Drug Market Challenges
1.3.4 Solid Tumor Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Solid Tumor Drug Players Revenue Ranking (2023)
2.2 Global Solid Tumor Drug Revenue by Company (2019-2024)
2.3 Key Companies Solid Tumor Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Solid Tumor Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Solid Tumor Drug
2.6 Solid Tumor Drug Market Competitive Analysis
2.6.1 Solid Tumor Drug Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Solid Tumor Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumor Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Small Molecules
3.1.2 Biologics
3.2 Global Solid Tumor Drug Sales Value by Type
3.2.1 Global Solid Tumor Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Solid Tumor Drug Sales Value, by Type (2019-2030)
3.2.3 Global Solid Tumor Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Neurology
4.1.3 Radiology
4.1.4 Others
4.2 Global Solid Tumor Drug Sales Value by Application
4.2.1 Global Solid Tumor Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Solid Tumor Drug Sales Value, by Application (2019-2030)
4.2.3 Global Solid Tumor Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Solid Tumor Drug Sales Value by Region
5.1.1 Global Solid Tumor Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Solid Tumor Drug Sales Value by Region (2019-2024)
5.1.3 Global Solid Tumor Drug Sales Value by Region (2025-2030)
5.1.4 Global Solid Tumor Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Solid Tumor Drug Sales Value, 2019-2030
5.2.2 North America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Solid Tumor Drug Sales Value, 2019-2030
5.3.2 Europe Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Solid Tumor Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Solid Tumor Drug Sales Value, 2019-2030
5.5.2 South America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Solid Tumor Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Solid Tumor Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Solid Tumor Drug Sales Value
6.3 United States
6.3.1 United States Solid Tumor Drug Sales Value, 2019-2030
6.3.2 United States Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Solid Tumor Drug Sales Value, 2019-2030
6.4.2 Europe Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Solid Tumor Drug Sales Value, 2019-2030
6.5.2 China Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Solid Tumor Drug Sales Value, 2019-2030
6.6.2 Japan Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Solid Tumor Drug Sales Value, 2019-2030
6.7.2 South Korea Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Solid Tumor Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Solid Tumor Drug Sales Value, 2019-2030
6.9.2 India Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Solid Tumor Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Profile
7.1.2 AstraZeneca Main Business
7.1.3 AstraZeneca Solid Tumor Drug Products, Services and Solutions
7.1.4 AstraZeneca Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.1.5 AstraZeneca Recent Developments
7.2 Biogen
7.2.1 Biogen Profile
7.2.2 Biogen Main Business
7.2.3 Biogen Solid Tumor Drug Products, Services and Solutions
7.2.4 Biogen Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.2.5 Biogen Recent Developments
7.3 Baxter
7.3.1 Baxter Profile
7.3.2 Baxter Main Business
7.3.3 Baxter Solid Tumor Drug Products, Services and Solutions
7.3.4 Baxter Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Celgene Corporation Recent Developments
7.4 Celgene Corporation
7.4.1 Celgene Corporation Profile
7.4.2 Celgene Corporation Main Business
7.4.3 Celgene Corporation Solid Tumor Drug Products, Services and Solutions
7.4.4 Celgene Corporation Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Celgene Corporation Recent Developments
7.5 Abbott Laboratories
7.5.1 Abbott Laboratories Profile
7.5.2 Abbott Laboratories Main Business
7.5.3 Abbott Laboratories Solid Tumor Drug Products, Services and Solutions
7.5.4 Abbott Laboratories Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Laboratories Recent Developments
7.6 Pfizer Inc
7.6.1 Pfizer Inc Profile
7.6.2 Pfizer Inc Main Business
7.6.3 Pfizer Inc Solid Tumor Drug Products, Services and Solutions
7.6.4 Pfizer Inc Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Inc Recent Developments
7.7 Amgen Limited & Amgen Ireland Limited
7.7.1 Amgen Limited & Amgen Ireland Limited Profile
7.7.2 Amgen Limited & Amgen Ireland Limited Main Business
7.7.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Products, Services and Solutions
7.7.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.7.5 Amgen Limited & Amgen Ireland Limited Recent Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Profile
7.8.2 Bristol-Myers Squibb Company Main Business
7.8.3 Bristol-Myers Squibb Company Solid Tumor Drug Products, Services and Solutions
7.8.4 Bristol-Myers Squibb Company Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol-Myers Squibb Company Recent Developments
7.9 GlaxoSmithKline plc.
7.9.1 GlaxoSmithKline plc. Profile
7.9.2 GlaxoSmithKline plc. Main Business
7.9.3 GlaxoSmithKline plc. Solid Tumor Drug Products, Services and Solutions
7.9.4 GlaxoSmithKline plc. Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.9.5 GlaxoSmithKline plc. Recent Developments
7.10 F. Hoffmann-La Roche Ltd.
7.10.1 F. Hoffmann-La Roche Ltd. Profile
7.10.2 F. Hoffmann-La Roche Ltd. Main Business
7.10.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Products, Services and Solutions
7.10.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.10.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.11 Eli Lilly and Company
7.11.1 Eli Lilly and Company Profile
7.11.2 Eli Lilly and Company Main Business
7.11.3 Eli Lilly and Company Solid Tumor Drug Products, Services and Solutions
7.11.4 Eli Lilly and Company Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.11.5 Eli Lilly and Company Recent Developments
7.12 Johnson & Johnson
7.12.1 Johnson & Johnson Profile
7.12.2 Johnson & Johnson Main Business
7.12.3 Johnson & Johnson Solid Tumor Drug Products, Services and Solutions
7.12.4 Johnson & Johnson Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.12.5 Johnson & Johnson Recent Developments
8 Industry Chain Analysis
8.1 Solid Tumor Drug Industrial Chain
8.2 Solid Tumor Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Solid Tumor Drug Sales Model
8.5.2 Sales Channel
8.5.3 Solid Tumor Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Solid Tumor Drug Product Introduction
1.2 Global Solid Tumor Drug Market Size Forecast
1.3 Solid Tumor Drug Market Trends & Drivers
1.3.1 Solid Tumor Drug Industry Trends
1.3.2 Solid Tumor Drug Market Drivers & Opportunity
1.3.3 Solid Tumor Drug Market Challenges
1.3.4 Solid Tumor Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Solid Tumor Drug Players Revenue Ranking (2023)
2.2 Global Solid Tumor Drug Revenue by Company (2019-2024)
2.3 Key Companies Solid Tumor Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Solid Tumor Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Solid Tumor Drug
2.6 Solid Tumor Drug Market Competitive Analysis
2.6.1 Solid Tumor Drug Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Solid Tumor Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumor Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Small Molecules
3.1.2 Biologics
3.2 Global Solid Tumor Drug Sales Value by Type
3.2.1 Global Solid Tumor Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Solid Tumor Drug Sales Value, by Type (2019-2030)
3.2.3 Global Solid Tumor Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Neurology
4.1.3 Radiology
4.1.4 Others
4.2 Global Solid Tumor Drug Sales Value by Application
4.2.1 Global Solid Tumor Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Solid Tumor Drug Sales Value, by Application (2019-2030)
4.2.3 Global Solid Tumor Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Solid Tumor Drug Sales Value by Region
5.1.1 Global Solid Tumor Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Solid Tumor Drug Sales Value by Region (2019-2024)
5.1.3 Global Solid Tumor Drug Sales Value by Region (2025-2030)
5.1.4 Global Solid Tumor Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Solid Tumor Drug Sales Value, 2019-2030
5.2.2 North America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Solid Tumor Drug Sales Value, 2019-2030
5.3.2 Europe Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Solid Tumor Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Solid Tumor Drug Sales Value, 2019-2030
5.5.2 South America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Solid Tumor Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Solid Tumor Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Solid Tumor Drug Sales Value
6.3 United States
6.3.1 United States Solid Tumor Drug Sales Value, 2019-2030
6.3.2 United States Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Solid Tumor Drug Sales Value, 2019-2030
6.4.2 Europe Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Solid Tumor Drug Sales Value, 2019-2030
6.5.2 China Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Solid Tumor Drug Sales Value, 2019-2030
6.6.2 Japan Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Solid Tumor Drug Sales Value, 2019-2030
6.7.2 South Korea Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Solid Tumor Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Solid Tumor Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Solid Tumor Drug Sales Value, 2019-2030
6.9.2 India Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Solid Tumor Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Profile
7.1.2 AstraZeneca Main Business
7.1.3 AstraZeneca Solid Tumor Drug Products, Services and Solutions
7.1.4 AstraZeneca Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.1.5 AstraZeneca Recent Developments
7.2 Biogen
7.2.1 Biogen Profile
7.2.2 Biogen Main Business
7.2.3 Biogen Solid Tumor Drug Products, Services and Solutions
7.2.4 Biogen Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.2.5 Biogen Recent Developments
7.3 Baxter
7.3.1 Baxter Profile
7.3.2 Baxter Main Business
7.3.3 Baxter Solid Tumor Drug Products, Services and Solutions
7.3.4 Baxter Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Celgene Corporation Recent Developments
7.4 Celgene Corporation
7.4.1 Celgene Corporation Profile
7.4.2 Celgene Corporation Main Business
7.4.3 Celgene Corporation Solid Tumor Drug Products, Services and Solutions
7.4.4 Celgene Corporation Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Celgene Corporation Recent Developments
7.5 Abbott Laboratories
7.5.1 Abbott Laboratories Profile
7.5.2 Abbott Laboratories Main Business
7.5.3 Abbott Laboratories Solid Tumor Drug Products, Services and Solutions
7.5.4 Abbott Laboratories Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Laboratories Recent Developments
7.6 Pfizer Inc
7.6.1 Pfizer Inc Profile
7.6.2 Pfizer Inc Main Business
7.6.3 Pfizer Inc Solid Tumor Drug Products, Services and Solutions
7.6.4 Pfizer Inc Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Inc Recent Developments
7.7 Amgen Limited & Amgen Ireland Limited
7.7.1 Amgen Limited & Amgen Ireland Limited Profile
7.7.2 Amgen Limited & Amgen Ireland Limited Main Business
7.7.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Products, Services and Solutions
7.7.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.7.5 Amgen Limited & Amgen Ireland Limited Recent Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Profile
7.8.2 Bristol-Myers Squibb Company Main Business
7.8.3 Bristol-Myers Squibb Company Solid Tumor Drug Products, Services and Solutions
7.8.4 Bristol-Myers Squibb Company Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol-Myers Squibb Company Recent Developments
7.9 GlaxoSmithKline plc.
7.9.1 GlaxoSmithKline plc. Profile
7.9.2 GlaxoSmithKline plc. Main Business
7.9.3 GlaxoSmithKline plc. Solid Tumor Drug Products, Services and Solutions
7.9.4 GlaxoSmithKline plc. Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.9.5 GlaxoSmithKline plc. Recent Developments
7.10 F. Hoffmann-La Roche Ltd.
7.10.1 F. Hoffmann-La Roche Ltd. Profile
7.10.2 F. Hoffmann-La Roche Ltd. Main Business
7.10.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Products, Services and Solutions
7.10.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.10.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.11 Eli Lilly and Company
7.11.1 Eli Lilly and Company Profile
7.11.2 Eli Lilly and Company Main Business
7.11.3 Eli Lilly and Company Solid Tumor Drug Products, Services and Solutions
7.11.4 Eli Lilly and Company Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.11.5 Eli Lilly and Company Recent Developments
7.12 Johnson & Johnson
7.12.1 Johnson & Johnson Profile
7.12.2 Johnson & Johnson Main Business
7.12.3 Johnson & Johnson Solid Tumor Drug Products, Services and Solutions
7.12.4 Johnson & Johnson Solid Tumor Drug Revenue (US$ Million) & (2019-2024)
7.12.5 Johnson & Johnson Recent Developments
8 Industry Chain Analysis
8.1 Solid Tumor Drug Industrial Chain
8.2 Solid Tumor Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Solid Tumor Drug Sales Model
8.5.2 Sales Channel
8.5.3 Solid Tumor Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Solid Tumor Drug Market Trends
Table 2. Solid Tumor Drug Market Drivers & Opportunity
Table 3. Solid Tumor Drug Market Challenges
Table 4. Solid Tumor Drug Market Restraints
Table 5. Global Solid Tumor Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Solid Tumor Drug Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Solid Tumor Drug Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Solid Tumor Drug Product Type
Table 9. Key Companies Time to Begin Mass Production of Solid Tumor Drug
Table 10. Global Solid Tumor Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumor Drug as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Solid Tumor Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Solid Tumor Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Solid Tumor Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Solid Tumor Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Solid Tumor Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Solid Tumor Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Solid Tumor Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Solid Tumor Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Solid Tumor Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Solid Tumor Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Solid Tumor Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Solid Tumor Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Solid Tumor Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Solid Tumor Drug Sales Value by Region (2019-2024) & (%)
Table 27. Global Solid Tumor Drug Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Solid Tumor Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Solid Tumor Drug Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Solid Tumor Drug Sales Value, (2025-2030) & (US$ Million)
Table 31. AstraZeneca Basic Information List
Table 32. AstraZeneca Description and Business Overview
Table 33. AstraZeneca Solid Tumor Drug Products, Services and Solutions
Table 34. Revenue (US$ Million) in Solid Tumor Drug Business of AstraZeneca (2019-2024)
Table 35. AstraZeneca Recent Developments
Table 36. Biogen Basic Information List
Table 37. Biogen Description and Business Overview
Table 38. Biogen Solid Tumor Drug Products, Services and Solutions
Table 39. Revenue (US$ Million) in Solid Tumor Drug Business of Biogen (2019-2024)
Table 40. Biogen Recent Developments
Table 41. Baxter Basic Information List
Table 42. Baxter Description and Business Overview
Table 43. Baxter Solid Tumor Drug Products, Services and Solutions
Table 44. Revenue (US$ Million) in Solid Tumor Drug Business of Baxter (2019-2024)
Table 45. Baxter Recent Developments
Table 46. Celgene Corporation Basic Information List
Table 47. Celgene Corporation Description and Business Overview
Table 48. Celgene Corporation Solid Tumor Drug Products, Services and Solutions
Table 49. Revenue (US$ Million) in Solid Tumor Drug Business of Celgene Corporation (2019-2024)
Table 50. Celgene Corporation Recent Developments
Table 51. Abbott Laboratories Basic Information List
Table 52. Abbott Laboratories Description and Business Overview
Table 53. Abbott Laboratories Solid Tumor Drug Products, Services and Solutions
Table 54. Revenue (US$ Million) in Solid Tumor Drug Business of Abbott Laboratories (2019-2024)
Table 55. Abbott Laboratories Recent Developments
Table 56. Pfizer Inc Basic Information List
Table 57. Pfizer Inc Description and Business Overview
Table 58. Pfizer Inc Solid Tumor Drug Products, Services and Solutions
Table 59. Revenue (US$ Million) in Solid Tumor Drug Business of Pfizer Inc (2019-2024)
Table 60. Pfizer Inc Recent Developments
Table 61. Amgen Limited & Amgen Ireland Limited Basic Information List
Table 62. Amgen Limited & Amgen Ireland Limited Description and Business Overview
Table 63. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Products, Services and Solutions
Table 64. Revenue (US$ Million) in Solid Tumor Drug Business of Amgen Limited & Amgen Ireland Limited (2019-2024)
Table 65. Amgen Limited & Amgen Ireland Limited Recent Developments
Table 66. Bristol-Myers Squibb Company Basic Information List
Table 67. Bristol-Myers Squibb Company Description and Business Overview
Table 68. Bristol-Myers Squibb Company Solid Tumor Drug Products, Services and Solutions
Table 69. Revenue (US$ Million) in Solid Tumor Drug Business of Bristol-Myers Squibb Company (2019-2024)
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. GlaxoSmithKline plc. Basic Information List
Table 72. GlaxoSmithKline plc. Description and Business Overview
Table 73. GlaxoSmithKline plc. Solid Tumor Drug Products, Services and Solutions
Table 74. Revenue (US$ Million) in Solid Tumor Drug Business of GlaxoSmithKline plc. (2019-2024)
Table 75. GlaxoSmithKline plc. Recent Developments
Table 76. F. Hoffmann-La Roche Ltd. Basic Information List
Table 77. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 78. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Products, Services and Solutions
Table 79. Revenue (US$ Million) in Solid Tumor Drug Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 80. F. Hoffmann-La Roche Ltd. Recent Developments
Table 81. Eli Lilly and Company Basic Information List
Table 82. Eli Lilly and Company Description and Business Overview
Table 83. Eli Lilly and Company Solid Tumor Drug Products, Services and Solutions
Table 84. Revenue (US$ Million) in Solid Tumor Drug Business of Eli Lilly and Company (2019-2024)
Table 85. Eli Lilly and Company Recent Developments
Table 86. Johnson & Johnson Basic Information List
Table 87. Johnson & Johnson Description and Business Overview
Table 88. Johnson & Johnson Solid Tumor Drug Products, Services and Solutions
Table 89. Revenue (US$ Million) in Solid Tumor Drug Business of Johnson & Johnson (2019-2024)
Table 90. Johnson & Johnson Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Solid Tumor Drug Downstream Customers
Table 94. Solid Tumor Drug Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Solid Tumor Drug Product Picture
Figure 2. Global Solid Tumor Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Solid Tumor Drug Report Years Considered
Figure 5. Global Solid Tumor Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Solid Tumor Drug Revenue in 2023
Figure 7. Solid Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Small Molecules Picture
Figure 9. Biologics Picture
Figure 10. Global Solid Tumor Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Solid Tumor Drug Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Oncology
Figure 13. Product Picture of Neurology
Figure 14. Product Picture of Radiology
Figure 15. Product Picture of Others
Figure 16. Global Solid Tumor Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global Solid Tumor Drug Sales Value Market Share by Application, 2023 & 2030
Figure 18. North America Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 19. North America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 20. Europe Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 21. Europe Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 22. Asia Pacific Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 23. Asia Pacific Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 24. South America Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 25. South America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 26. Middle East & Africa Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 27. Middle East & Africa Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 28. Key Countries/Regions Solid Tumor Drug Sales Value (%), (2019-2030)
Figure 29. United States Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 30. United States Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 31. United States Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 32. Europe Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 33. Europe Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 34. Europe Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 35. China Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 36. China Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 37. China Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 38. Japan Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 39. Japan Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 40. Japan Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 41. South Korea Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 42. South Korea Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 43. South Korea Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 44. Southeast Asia Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 46. Southeast Asia Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 47. India Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 48. India Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 49. India Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 50. Solid Tumor Drug Industrial Chain
Figure 51. Solid Tumor Drug Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Table 1. Solid Tumor Drug Market Trends
Table 2. Solid Tumor Drug Market Drivers & Opportunity
Table 3. Solid Tumor Drug Market Challenges
Table 4. Solid Tumor Drug Market Restraints
Table 5. Global Solid Tumor Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Solid Tumor Drug Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Solid Tumor Drug Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Solid Tumor Drug Product Type
Table 9. Key Companies Time to Begin Mass Production of Solid Tumor Drug
Table 10. Global Solid Tumor Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumor Drug as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Solid Tumor Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Solid Tumor Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Solid Tumor Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Solid Tumor Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Solid Tumor Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Solid Tumor Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Solid Tumor Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Solid Tumor Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Solid Tumor Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Solid Tumor Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Solid Tumor Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Solid Tumor Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Solid Tumor Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Solid Tumor Drug Sales Value by Region (2019-2024) & (%)
Table 27. Global Solid Tumor Drug Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Solid Tumor Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Solid Tumor Drug Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Solid Tumor Drug Sales Value, (2025-2030) & (US$ Million)
Table 31. AstraZeneca Basic Information List
Table 32. AstraZeneca Description and Business Overview
Table 33. AstraZeneca Solid Tumor Drug Products, Services and Solutions
Table 34. Revenue (US$ Million) in Solid Tumor Drug Business of AstraZeneca (2019-2024)
Table 35. AstraZeneca Recent Developments
Table 36. Biogen Basic Information List
Table 37. Biogen Description and Business Overview
Table 38. Biogen Solid Tumor Drug Products, Services and Solutions
Table 39. Revenue (US$ Million) in Solid Tumor Drug Business of Biogen (2019-2024)
Table 40. Biogen Recent Developments
Table 41. Baxter Basic Information List
Table 42. Baxter Description and Business Overview
Table 43. Baxter Solid Tumor Drug Products, Services and Solutions
Table 44. Revenue (US$ Million) in Solid Tumor Drug Business of Baxter (2019-2024)
Table 45. Baxter Recent Developments
Table 46. Celgene Corporation Basic Information List
Table 47. Celgene Corporation Description and Business Overview
Table 48. Celgene Corporation Solid Tumor Drug Products, Services and Solutions
Table 49. Revenue (US$ Million) in Solid Tumor Drug Business of Celgene Corporation (2019-2024)
Table 50. Celgene Corporation Recent Developments
Table 51. Abbott Laboratories Basic Information List
Table 52. Abbott Laboratories Description and Business Overview
Table 53. Abbott Laboratories Solid Tumor Drug Products, Services and Solutions
Table 54. Revenue (US$ Million) in Solid Tumor Drug Business of Abbott Laboratories (2019-2024)
Table 55. Abbott Laboratories Recent Developments
Table 56. Pfizer Inc Basic Information List
Table 57. Pfizer Inc Description and Business Overview
Table 58. Pfizer Inc Solid Tumor Drug Products, Services and Solutions
Table 59. Revenue (US$ Million) in Solid Tumor Drug Business of Pfizer Inc (2019-2024)
Table 60. Pfizer Inc Recent Developments
Table 61. Amgen Limited & Amgen Ireland Limited Basic Information List
Table 62. Amgen Limited & Amgen Ireland Limited Description and Business Overview
Table 63. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Products, Services and Solutions
Table 64. Revenue (US$ Million) in Solid Tumor Drug Business of Amgen Limited & Amgen Ireland Limited (2019-2024)
Table 65. Amgen Limited & Amgen Ireland Limited Recent Developments
Table 66. Bristol-Myers Squibb Company Basic Information List
Table 67. Bristol-Myers Squibb Company Description and Business Overview
Table 68. Bristol-Myers Squibb Company Solid Tumor Drug Products, Services and Solutions
Table 69. Revenue (US$ Million) in Solid Tumor Drug Business of Bristol-Myers Squibb Company (2019-2024)
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. GlaxoSmithKline plc. Basic Information List
Table 72. GlaxoSmithKline plc. Description and Business Overview
Table 73. GlaxoSmithKline plc. Solid Tumor Drug Products, Services and Solutions
Table 74. Revenue (US$ Million) in Solid Tumor Drug Business of GlaxoSmithKline plc. (2019-2024)
Table 75. GlaxoSmithKline plc. Recent Developments
Table 76. F. Hoffmann-La Roche Ltd. Basic Information List
Table 77. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 78. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Products, Services and Solutions
Table 79. Revenue (US$ Million) in Solid Tumor Drug Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 80. F. Hoffmann-La Roche Ltd. Recent Developments
Table 81. Eli Lilly and Company Basic Information List
Table 82. Eli Lilly and Company Description and Business Overview
Table 83. Eli Lilly and Company Solid Tumor Drug Products, Services and Solutions
Table 84. Revenue (US$ Million) in Solid Tumor Drug Business of Eli Lilly and Company (2019-2024)
Table 85. Eli Lilly and Company Recent Developments
Table 86. Johnson & Johnson Basic Information List
Table 87. Johnson & Johnson Description and Business Overview
Table 88. Johnson & Johnson Solid Tumor Drug Products, Services and Solutions
Table 89. Revenue (US$ Million) in Solid Tumor Drug Business of Johnson & Johnson (2019-2024)
Table 90. Johnson & Johnson Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Solid Tumor Drug Downstream Customers
Table 94. Solid Tumor Drug Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Solid Tumor Drug Product Picture
Figure 2. Global Solid Tumor Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Solid Tumor Drug Report Years Considered
Figure 5. Global Solid Tumor Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Solid Tumor Drug Revenue in 2023
Figure 7. Solid Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Small Molecules Picture
Figure 9. Biologics Picture
Figure 10. Global Solid Tumor Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Solid Tumor Drug Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Oncology
Figure 13. Product Picture of Neurology
Figure 14. Product Picture of Radiology
Figure 15. Product Picture of Others
Figure 16. Global Solid Tumor Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global Solid Tumor Drug Sales Value Market Share by Application, 2023 & 2030
Figure 18. North America Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 19. North America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 20. Europe Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 21. Europe Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 22. Asia Pacific Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 23. Asia Pacific Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 24. South America Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 25. South America Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 26. Middle East & Africa Solid Tumor Drug Sales Value (2019-2030) & (US$ Million)
Figure 27. Middle East & Africa Solid Tumor Drug Sales Value by Country (%), 2023 VS 2030
Figure 28. Key Countries/Regions Solid Tumor Drug Sales Value (%), (2019-2030)
Figure 29. United States Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 30. United States Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 31. United States Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 32. Europe Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 33. Europe Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 34. Europe Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 35. China Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 36. China Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 37. China Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 38. Japan Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 39. Japan Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 40. Japan Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 41. South Korea Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 42. South Korea Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 43. South Korea Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 44. Southeast Asia Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 46. Southeast Asia Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 47. India Solid Tumor Drug Sales Value, (2019-2030) & (US$ Million)
Figure 48. India Solid Tumor Drug Sales Value by Type (%), 2023 VS 2030
Figure 49. India Solid Tumor Drug Sales Value by Application (%), 2023 VS 2030
Figure 50. Solid Tumor Drug Industrial Chain
Figure 51. Solid Tumor Drug Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232